ENDRA Life Sciences Inc. (NDRA) - 10-Q Summary
Business Context and Reporting Period
This Quarterly Report on Form 10-Q covers the period ended September 30, 2024. ENDRA Life Sciences Inc. is a medical technology company developing Thermo-Acoustic Enhanced Ultrasound (TAEUS) technology for non-invasive tissue characterization, specifically targeting the diagnosis of nonalcoholic fatty liver disease (NAFLD). The company has received CE mark approval for its TAEUS FLIP system in the EU but is currently pursuing FDA de novo clearance in the United States. As of the reporting date, the company has generated no commercial revenue.
Key Financial Metrics
| Metric | Three Months Ended Sep 30, 2024 | Nine Months Ended Sep 30, 2024 | Balance Sheet (Sep 30, 2024) |
|---|---|---|---|
| Revenue | $0 | $0 | - |
| Net Loss | $(2,354,090) | $(7,358,943) | - |
| Operating Expenses | $1,509,014 | $6,520,408 | - |
| Cash and Cash Equivalents | - | - | $4,745,187 |
| Total Assets | - | - | $8,379,110 |
| Total Liabilities | - | - | $1,774,424 |
| Working Capital | - | - | $4,148,262 |
| Accumulated Deficit | - | - | $(99,289,095) |
Other Expenses: The nine-month net loss was significantly impacted by non-cash items related to warrant accounting, including a $7.3 million warrant expense, offset by a $3.3 million gain from changes in fair value of warrant liability and a $3.1 million gain on settlement of warrant exercises.
Material Changes vs. Prior Period
- Expense Reduction: Total operating expenses decreased by approximately 28% for the nine months ended September 30, 2024, compared to the same period in 2023 ($6.52 million vs. $9.06 million). This was driven by significant reductions in Research and Development (down 42%) and General and Administrative expenses (down 12%).
- Capital Structure Changes: The company completed a registered offering in June 2024, raising net proceeds of approximately $7.34 million through the sale of common stock and pre-funded warrants. Additionally, a 1-for-50 reverse stock split was effected in August 2024, and a subsequent 1-for-35 reverse split was approved in November 2024 (subsequent event).
- Warrant Liability: A significant warrant liability of $910,556 was recorded as of September 30, 2024, compared to zero in the prior year, due to the classification of Series A and Series B warrants as liabilities under ASC 815.
- Debt Repayment: The company repaid its remaining balance on a Canadian Emergency Business Account loan from TD Bank during the nine-month period.
Outlook, Risks, and Management Commentary
- Going Concern: Management has raised substantial doubt about the company's ability to continue as a going concern. With an accumulated deficit of nearly $100 million and no revenue, the company requires additional financing to fund operations for the next 12 months and to complete commercialization.
- Regulatory Path: The company anticipates completing necessary clinical studies for its NAFLD TAEUS system by Q4 2024 or Q1 2025, with a new de novo submission to the FDA expected in the first half of 2025.
- Liquidity Constraints: While the company raised capital in June 2024, it is restricted from issuing common stock or convertible securities involving a Variable Rate Transaction (including its ATM program) for 180 days following the offering closing. This limits immediate access to certain capital markets.
- Internal Controls: Management concluded that disclosure controls and procedures were not effective as of September 30, 2024, citing a material weakness due to insufficient accounting personnel to segregate duties.
- Inventory Reserve: The company established a 5% inventory shrinkage reserve ($142,733) due to potential damage and longer timeframes for initial sales.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $4.75 million cash balance against the burn rate, considering the 180-day restriction on ATM sales and the need for additional funding to reach FDA submission.
- Warrant Liability Volatility: Monitor the fair value of the $910,556 warrant liability, as fluctuations in stock price and volatility assumptions will directly impact reported net income/loss.
- Reverse Stock Split Impact: Confirm the finalization and market impact of the November 2024 1-for-35 reverse stock split and its effect on share count and liquidity.
- FDA Timeline: Track the progress of the clinical studies and the timing of the de novo submission to the FDA, as this is the primary catalyst for future revenue.
- Internal Control Remediation: Assess the company's progress in hiring additional accounting personnel to remediate the identified material weakness in internal controls.